These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33614378)

  • 21. Recessive mutation in GALNT3 causes hyperphosphatemic familial tumoral calcinosis associated with chronic recurrent multifocal osteomyelitis.
    Albaramki J; Dmour H; Shboul M; Bonnard C; Venkatesh B; Odeh R
    Turk J Pediatr; 2019; 61(1):130-133. PubMed ID: 31559735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
    Garringer HJ; Fisher C; Larsson TE; Davis SI; Koller DL; Cullen MJ; Draman MS; Conlon N; Jain A; Fedarko NS; Dasgupta B; White KE
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4037-42. PubMed ID: 16868048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive.
    Ichikawa S; Lyles KW; Econs MJ
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2420-3. PubMed ID: 15687324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel
    Zuo Q; Yang W; Liu B; Yan D; Wang Z; Wang H; Deng W; Cao X; Yang J
    Front Endocrinol (Lausanne); 2022; 13():1008800. PubMed ID: 36213261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis.
    Barbieri AM; Filopanti M; Bua G; Beck-Peccoz P
    J Hum Genet; 2007; 52(5):464-468. PubMed ID: 17351710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
    Ichikawa S; Guigonis V; Imel EA; Courouble M; Heissat S; Henley JD; Sorenson AH; Petit B; Lienhardt A; Econs MJ
    J Clin Endocrinol Metab; 2007 May; 92(5):1943-7. PubMed ID: 17311862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC).
    Vieira AR; Lee M; Vairo F; Loguercio Leite JC; Munerato MC; Visioli F; D'Ávila SR; Wang SK; Choi M; Simmer JP; Hu JC
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Dec; 120(6):e235-9. PubMed ID: 26337219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
    Frishberg Y; Topaz O; Bergman R; Behar D; Fisher D; Gordon D; Richard G; Sprecher E
    J Mol Med (Berl); 2005 Jan; 83(1):33-8. PubMed ID: 15599692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3.
    Joseph L; Hing SN; Presneau N; O'Donnell P; Diss T; Idowu BD; Joseph S; Flanagan AM; Delaney D
    Skeletal Radiol; 2010 Jan; 39(1):63-8. PubMed ID: 19830424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Sole Case of the FGF23 Gene Mutation c.202A>G (p.Thr68Ala) Associated with Multiple Severe Vascular Aneurysms and a Hyperphosphatemic Variant of Tumoral Calcinosis-A Case Report.
    Ivanova NG
    Life (Basel); 2024 May; 14(5):. PubMed ID: 38792634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome.
    Peluso G; Tian E; Abusleme L; Munemasa T; Mukaibo T; Ten Hagen KG
    J Biol Chem; 2020 Jan; 295(5):1411-1425. PubMed ID: 31882545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
    Folsom LJ; Imel EA
    Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in
    Döneray H; Özden A; Gürbüz K
    J Clin Res Pediatr Endocrinol; 2022 Jun; 14(2):239-243. PubMed ID: 33685073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis.
    Masi L; Gozzini A; Franchi A; Campanacci D; Amedei A; Falchetti A; Franceschelli F; Marcucci G; Tanini A; Capanna R; Brandi ML
    J Bone Joint Surg Am; 2009 May; 91(5):1190-8. PubMed ID: 19411468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.
    Chefetz I; Heller R; Galli-Tsinopoulou A; Richard G; Wollnik B; Indelman M; Koerber F; Topaz O; Bergman R; Sprecher E; Schoenau E
    Hum Genet; 2005 Nov; 118(2):261-6. PubMed ID: 16151858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone Involvement in Hyperphosphatemic Familial Tumoral Calcinosis: A New Phenotypic Presentation.
    Freedman JD; Novak R; Bratman Morag S; Avitan-Hersh E; Nikomarov D
    Rambam Maimonides Med J; 2021 Jul; 12(3):. PubMed ID: 34270404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Cross-Sectional Cohort Study of the Effects of FGF23 Deficiency and Hyperphosphatemia on Dental Structures in Hyperphosphatemic Familial Tumoral Calcinosis.
    Lee AE; Chu EY; Gardner PJ; Duverger O; Saikali A; Wang SK; Gafni RI; Hartley IR; Ten Hagen KG; Somerman MJ; Collins MT
    JBMR Plus; 2021 May; 5(5):e10470. PubMed ID: 33977199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?
    Claramunt-Taberner D; Bertholet-Thomas A; Carlier MC; Dijoud F; Chotel F; Silve C; Bacchetta J
    Pediatr Nephrol; 2018 Jul; 33(7):1263-1267. PubMed ID: 29594503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
    Ichikawa S; Imel EA; Sorenson AH; Severe R; Knudson P; Harris GJ; Shaker JL; Econs MJ
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4472-5. PubMed ID: 16940445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
    Ramnitz MS; Gourh P; Goldbach-Mansky R; Wodajo F; Ichikawa S; Econs MJ; White KE; Molinolo A; Chen MY; Heller T; Del Rivero J; Seo-Mayer P; Arabshahi B; Jackson MB; Hatab S; McCarthy E; Guthrie LC; Brillante BA; Gafni RI; Collins MT
    J Bone Miner Res; 2016 Oct; 31(10):1845-1854. PubMed ID: 27164190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.